{"log_id": 2770053827620445033, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 0, "average": 0.999827, "min": 0.999685}, "location": {"width": 104, "top": 262, "height": 25, "left": 270}, "words": "实验室异常"}, {"probability": {"variance": 0, "average": 0.999448, "min": 0.998506}, "location": {"width": 105, "top": 336, "height": 26, "left": 270}, "words": "血液学异常"}, {"probability": {"variance": 0, "average": 0.999714, "min": 0.999714}, "location": {"width": 22, "top": 337, "height": 27, "left": 1158}, "words": "督"}, {"probability": {"variance": 1.2e-05, "average": 0.996501, "min": 0.990019}, "location": {"width": 101, "top": 376, "height": 22, "left": 275}, "words": "中性粒细胞"}, {"probability": {"variance": 0.000402, "average": 0.993065, "min": 0.877673}, "location": {"width": 746, "top": 407, "height": 35, "left": 270}, "words": "在6个月的对照试验中,托珠单抗8mg/kg+ DMARD组有3.4%的患者出现中性粒细"}, {"probability": {"variance": 0.021836, "average": 0.935134, "min": 0.434679}, "location": {"width": 767, "top": 446, "height": 35, "left": 231}, "words": "胞计数低于1×10%,而安慰剂+ DMARD组患者<0.1%。ANC低于1109L的病例中"}, {"probability": {"variance": 0.00018, "average": 0.994549, "min": 0.939606}, "location": {"width": 784, "top": 486, "height": 33, "left": 231}, "words": "约有一半出现在开始治疗的8周内。托珠单抗8mg/kg+ DMARD组报告有0.3%的患者计"}, {"probability": {"variance": 0.003774, "average": 0.9802, "min": 0.650109}, "location": {"width": 784, "top": 525, "height": 33, "left": 232}, "words": "数低于0.5×10/L(见【注意事项】实验室检查部分)。中性粒细胞低于1×10%的情况"}, {"probability": {"variance": 0, "average": 0.999556, "min": 0.998585}, "location": {"width": 339, "top": 569, "height": 27, "left": 234}, "words": "与严重感染的发生率之间无明显的关系"}, {"probability": {"variance": 3.1e-05, "average": 0.997488, "min": 0.96795}, "location": {"width": 747, "top": 603, "height": 34, "left": 273}, "words": "在全部对照和全部暴露人群中,中性粒细胞计数的下降方式和发生率与6个月对照试"}, {"probability": {"variance": 1e-05, "average": 0.997607, "min": 0.992047}, "location": {"width": 101, "top": 650, "height": 26, "left": 233}, "words": "验数据一致"}, {"probability": {"variance": 0.000636, "average": 0.981178, "min": 0.945523}, "location": {"width": 64, "top": 689, "height": 25, "left": 276}, "words": "血小板"}, {"probability": {"variance": 0.000154, "average": 0.995069, "min": 0.927017}, "location": {"width": 744, "top": 721, "height": 33, "left": 275}, "words": "在6个月的对照试验中,托珠单抗8mg/kg联合传统 DMARDS治疗组中有1.7%的患"}, {"probability": {"variance": 0.012328, "average": 0.966612, "min": 0.397883}, "location": {"width": 786, "top": 760, "height": 34, "left": 235}, "words": "者血小板计数低于100x103l,而安慰剂联合传统 DMARDS治疗组<1%,未发生相关出"}, {"probability": {"variance": 2e-06, "average": 0.998825, "min": 0.993497}, "location": {"width": 365, "top": 804, "height": 26, "left": 236}, "words": "血事件(见【注意事项】实验室检查部分"}, {"probability": {"variance": 8e-06, "average": 0.998709, "min": 0.983016}, "location": {"width": 747, "top": 837, "height": 36, "left": 275}, "words": "在全部对照和全部暴露人群中,血小板计数的下降方式和发生率与6个月临床对照试"}, {"probability": {"variance": 6e-06, "average": 0.998183, "min": 0.99364}, "location": {"width": 184, "top": 885, "height": 25, "left": 236}, "words": "验中所得的结果相似"}, {"probability": {"variance": 1e-06, "average": 0.998455, "min": 0.997371}, "location": {"width": 86, "top": 923, "height": 26, "left": 276}, "words": "肝酶升高"}, {"probability": {"variance": 9.9e-05, "average": 0.996589, "min": 0.937366}, "location": {"width": 747, "top": 957, "height": 33, "left": 276}, "words": "在6个月的对照试验中,在接受托珠单抗8mg/kg的患者中有2.1%丙氨酸氨基转移酶"}, {"probability": {"variance": 0.001238, "average": 0.990564, "min": 0.781917}, "location": {"width": 781, "top": 994, "height": 36, "left": 242}, "words": "天门冬氨酸氨基转移酶( ALT/AST)升高3倍以上,MTX组为4.9%,托珠单抗"}, {"probability": {"variance": 0.000287, "average": 0.991889, "min": 0.915727}, "location": {"width": 790, "top": 1033, "height": 39, "left": 235}, "words": "8mg/kg+ DMARD组为6.5%,安慰剂+ DMARD组为1.5%。在应用托珠单抗的同时加用有"}, {"probability": {"variance": 0.000186, "average": 0.994953, "min": 0.917844}, "location": {"width": 786, "top": 1073, "height": 35, "left": 238}, "words": "潜在肝毒性的药物(如MTX),会使氨基转移酶升高的发生率增加。在单独应用托珠单抗"}, {"probability": {"variance": 0.001232, "average": 0.985897, "min": 0.797697}, "location": {"width": 786, "top": 1112, "height": 35, "left": 240}, "words": "治疗组中,0.7%的患者ALT/AST升高5倍以上,托珠单抗+ DMARD组则为1.4%,这其"}, {"probability": {"variance": 1.2e-05, "average": 0.997855, "min": 0.982094}, "location": {"width": 787, "top": 1152, "height": 35, "left": 240}, "words": "中的大部分患者都停止了托珠单抗治疗(见【注意事项】实验室检查部分)。这些氨基转"}, {"probability": {"variance": 0.000199, "average": 0.996684, "min": 0.910171}, "location": {"width": 788, "top": 1191, "height": 35, "left": 240}, "words": "移酶的升高不伴随任何临床相关的直接胆红素升高,也不伴随有临床表现的肝炎或肝功能"}, {"probability": {"variance": 0.00053, "average": 0.993415, "min": 0.85833}, "location": {"width": 787, "top": 1230, "height": 35, "left": 241}, "words": "不全。所有对照人群中接受托珠单抗8mg/kg+ DMARD治疗的患者在常规实验室检查期间"}, {"probability": {"variance": 0.007013, "average": 0.978648, "min": 0.6138}, "location": {"width": 370, "top": 1275, "height": 26, "left": 243}, "words": "间接胆红素高于正常上限的发生率为6.2%"}, {"probability": {"variance": 4e-06, "average": 0.99838, "min": 0.99376}, "location": {"width": 746, "top": 1309, "height": 33, "left": 282}, "words": "在全部对照和全部暴露人群中, ALT/AST的升高方式和发生率与6个月对照试验数据"}, {"probability": {"variance": 0, "average": 0.999887, "min": 0.999887}, "location": {"width": 24, "top": 1356, "height": 24, "left": 263}, "words": "致"}, {"probability": {"variance": 6.5e-05, "average": 0.995517, "min": 0.977478}, "location": {"width": 125, "top": 1393, "height": 25, "left": 286}, "words": "血脂参数升高"}, {"probability": {"variance": 1e-05, "average": 0.998591, "min": 0.981148}, "location": {"width": 726, "top": 1426, "height": 35, "left": 284}, "words": "在6个月的对照试验中,接受托珠单抗治疗的患者进行常规实验室检查发现血脂参"}, {"probability": {"variance": 0.017393, "average": 0.943017, "min": 0.413196}, "location": {"width": 825, "top": 1451, "height": 46, "left": 256}, "words": "(总胆固醇、低密度脂蛋白、高密度脂蛋白、甘油三酯)升高。在临床试验托珠抗"}, {"probability": {"variance": 0.019075, "average": 0.930947, "min": 0.476357}, "location": {"width": 790, "top": 1501, "height": 40, "left": 244}, "words": "组中,约有24%的患者总胆固醇出现持续升高>6.2mmol/L(240mg/d),约有5的患者"}, {"probability": {"variance": 0, "average": 0.920261, "min": 0.920261}, "location": {"width": 39, "top": 1494, "height": 34, "left": 1090}, "words": "做"}, {"probability": {"variance": 0, "average": 0.893964, "min": 0.893964}, "location": {"width": 40, "top": 1525, "height": 33, "left": 1096}, "words": " aint"}, {"probability": {"variance": 0.01429, "average": 0.944502, "min": 0.517114}, "location": {"width": 426, "top": 1551, "height": 26, "left": 247}, "words": "低密度脂蛋白持续升高至≥4.1mmol/(160mg/dl)"}], "language": 3}